Biotech ETFs rally on AI drug discovery and M&A

Biotech exchange-traded funds rose in the first half of 2026 as advances in AI-driven drug discovery and a surge in mergers and acquisitions drew investor interest. The State Street SPDR S&P Biotech ETF (XBI) gained 17.9% in H1 2026 and returned 77.9% over the one-year period ending June 22, 2026.

Other sector ETFs posted varied one-year returns: the iShares Biotechnology ETF (IBB) returned 41.4%, the VanEck Biotech ETF (BBH) returned 24.8%, the Invesco Biotechnology & Genome ETF (PBE) returned 35.9% and the ALPS Medical Breakthroughs ETF (SBIO) returned 95.5%.

Fund size and index rules affected performance. XBI follows an equal-weight index and holds about $9 billion in assets, increasing exposure to small- and mid-cap companies. IBB, with roughly $8.1 billion, favors large-cap names. BBH is concentrated in large commercial firms such as Amgen and Gilead Sciences. PBE uses a multi-factor approach emphasizing genetic engineering and related technologies. SBIO requires constituents to be in clinical phase II or III trials, a rule that increased its sensitivity to clinical readouts and deal activity.

Two industry trends coincided with higher deal activity. Large drugmakers face an estimated $280 billion patent cliff through 2028, prompting acquisitions of clinical-stage pipelines. Recent transactions include Novartis’s purchase of Avidity Biosciences and Merck’s acquisition of Terns Pharmaceuticals. Advances in computational biology and AI foundation models that predict protein structures and design biological sequences are shortening early discovery timelines and lowering early-stage costs.

Dario Amodei, CEO of Anthropic, described advanced generative AI models as ‘compressing decades of biological legwork into short experimental cycles.’ Developers and corporate buyers are directing more resources toward later-stage clinical development where potential acquirers focus.

Macroeconomic and policy shifts have coincided with the sector’s gains. Expectations for interest-rate cuts and clearer guidance on drug pricing reduced the cost of capital for potential buyers and eased some regulatory uncertainty for companies planning clinical programs or seeking acquisition financing.

ETF construction drives different risk exposures. Equal-weight funds increase exposure to smaller clinical-stage companies that are common acquisition targets, while market-cap-weighted or concentrated funds emphasize revenue-generating companies. SBIO’s clinical-trial requirement makes it more sensitive to trial outcomes and M&A flow.

The biotech ETF rally follows several years of sector weakness and reflects recent M&A activity and advances in AI-driven discovery. Market participants continue to watch deal announcements and clinical readouts for information on future performance.